Replies to post #871 on Ampio Pharmaceuticals Inc (AMPE)

[0210]

"Ampio’s lead drug, Ampion, is backed by an extensive patent portfolio with intellectual property protection extending through 2032, and will be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the biologics price competition and innovation act (“BPCIA”)."

SOURCE: ENGLEWOOD, Colo., October 28, 2020, /PRNewswire/UPDATE ON COVID-19 CLINICAL TRIAL ACTIVITIES.

[TJG]

I have been making it a point to add shares ever since I arrived here when the first Colorado intravenous news broke... this new round of nebulizer tests, if successful will set this up for a huge run and possible buy out from a major pharma company. They are no longer just a knee and joint biotech company.